Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

Código QR

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

Qing Qiao,1 Mario JNM Ouwens,1 Susan Grandy,2 Kristina Johnsson,1 Karel Kostev3 1Global Medicines Development, AstraZeneca, Gothenburg, Sweden; 2Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA; 3Epidemiology and Evidence-Based Medicine, Real-World Evidence Solutions, IMS Health, Fra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qiao Q, Ouwens MJNM, Grandy S, Johnsson K, Kostev K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	type 2 diabetes GLP-1 receptor agonists adherence Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/9306438065de468c9331ee1729c05140
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh RA, et al.
Publicado: (2020)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
por: Yanbin Dong, et al.
Publicado: (2021)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019)

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
por: Toomas Jagomäe, et al.
Publicado: (2021)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary J, et al.
Publicado: (2010)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021)

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
por: Orme ME, et al.
Publicado: (2017)

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
por: Torres-Llenza V, et al.
Publicado: (2018)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury AC, et al.
Publicado: (2021)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson AM, et al.
Publicado: (2016)

Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
por: Wirta DL, et al.
Publicado: (2021)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders WB, et al.
Publicado: (2016)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Masao Koike, et al.
Publicado: (2021)

Activation of the GLP-1 receptor by chloropyrimidine derivatives
por: Shaikha S. AlNeyadi, et al.
Publicado: (2021)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen J, et al.
Publicado: (2017)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
por: Shen J, et al.
Publicado: (2018)

Potential benefit of dolutegravir once daily: efficacy and safety
por: Fantauzzi A, et al.
Publicado: (2013)

Once-daily treatment of ADHD with guanfacine: patient implications
por: Brandon C Strange
Publicado: (2008)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
por: Kutoh Eiji, et al.
Publicado: (2019)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
por: Lee SP, et al.
Publicado: (2019)

GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions
por: Hui Li, et al.
Publicado: (2021)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
por: Yury Ivanovich Suntsov
Publicado: (2012)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud A, et al.
Publicado: (2015)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
por: Marina V. Shestakova, et al.
Publicado: (2017)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome G, et al.
Publicado: (2020)

Gabapentin for once-daily treatment of post-herpetic neuralgia: a review
por: Beal B, et al.
Publicado: (2012)

Effect of once-daily FDC treatment era on initiation of cART
por: David M Mosen, et al.
Publicado: (2010)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson SE
Publicado: (2011)

Once and Twice
por: Richard S. Kayne
Publicado: (2015)

Once is not enough
por: Susan, Jacqueline

Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy
por: Ameya R. Kirtane, et al.
Publicado: (2018)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen AB, et al.
Publicado: (2013)

Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by <named-content content-type="genus-species">Enterococcus faecalis</named-content> Metalloprotease GelE
por: Stephanie L. LeValley, et al.
Publicado: (2020)

Once ensayos filosóficos
por: Terra,Constanza
Publicado: (2011)

HEM/ONC today
Publicado: (1999)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann KV, et al.
Publicado: (2014)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Jason Seewoodhary, et al.
Publicado: (2010)